In our experimental setting, Stx2a added to human blood increased the release of blood cell-derived EVs (10,400–20,800 g), similar to those found in patients with HUS or in STEC-infected children the day before the onset of the syndrome. The gene discussed is STX2; the disease is hemolytic-uremic syndrome.